Abstract: In embodiments, a glass composition may include: greater than or equal to 71 mol. % and less than or equal to 83 mol. % SiO2; greater than or equal to 1 mol. % and less than or equal to 11 mol. % Al2O3; greater than or equal to 5 mol. % and less than or equal to 18 mol. % alkali oxide, the alkali oxide comprising greater than 3 mol. % Li2O and at least one of Na2O and K2O; greater than or equal to 1 mol. % and less than or equal to 8 mol. % alkaline earth oxide, the alkaline earth oxide comprising MgO and at least one of CaO, BaO, and SrO; and at least one of TiO2, ZrO2, HfO2, La2O3 and Y2O3, wherein TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than 0 mol. % and less than or equal to 6 mol. % and Al2O3+TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than or equal to 2 mol. % and less than or equal to 12 mol. %.

Abstract: The embodiments described herein relate to low temperature moldable sheet forming glass compositions and glass articles formed from the same. In various embodiments, the glass composition comprises from about 60 mol. % to about 67 mol. % SiO2, from about 6 mol. % to about 11 mol. % B2O3, from about 4.5 mol. % to about 11 mol. % Li2O, Al2O3, Na2O, and K2O. The glass composition also includes greater than about 2 mol. % RO, where RO are divalent metal oxides, and R2O from about 14 mol. % to about 20 mol. %, where R2O are alkali metal oxides. The glass composition also has a glass transition temperature Tg of less than about 500° C., a softening point of less than about 650° C., and a coefficient of thermal expansion (CTE) of less than about 85×10?7K?1.

Abstract: The embodiments described herein relate to low temperature moldable sheet forming glass compositions and glass articles formed from the same. In various embodiments, the glass composition comprises from about 60 mol. % to about 67 mol. % SiO2, from about 6 mol. % to about 11 mol. % B2O3, from about 4.5 mol. % to about 11 mol. % Li2O, Al2O3, Na2O, and K2O. The glass composition also includes greater than about 2 mol. % RO, where RO are divalent metal oxides, and R2O from about 14 mol. % to about 20 mol. %, where R2O are alkali metal oxides. The glass composition also has a glass transition temperature Tg of less than about 500° C., a softening point of less than about 650° C., and a coefficient of thermal expansion (CTE) of less than about 85×10?7K?1.

Abstract: The embodiments described herein relate to low temperature moldable sheet forming glass compositions and glass articles formed from the same. In various embodiments, the glass composition comprises from about 60 mol. % to about 67 mol. % SiO2, from about 6 mol. % to about 11 mol. % B2O3, from about 4.5 mol. % to about 11 mol. % Li2O, Al2O3, Na2O, and K2O. The glass composition also includes greater than about 2 mol. % RO, where RO are divalent metal oxides, and R2O from about 14 mol. % to about 20 mol. %, where R2O are alkali metal oxides. The glass composition also has a glass transition temperature Tg of less than about 500 C, a softening point of less than about 650 C, and a coefficient of thermal expansion (CTE) of less than about 85×10?7 K?1.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

Abstract: Chemically durable glass compositions are disclosed. In embodiments, the glass composition includes: 48 mol. % to 61 mol. % SiO2; 0 mol. % to 1 mol. % Al2O3; 7 mol. % to 20 mol. % B2O3; 9 mol. % to 16 mol. % R2O, where R2O is a sum of alkali oxides present in the glass composition; 9 mol. % to 15 mol. % Na2O; and 8 mol. % to 21 mol. % ZnO. The glass composition may be substantially free of Li2O. RO (mol. %)<0.5×ZnO (mol. %), where RO is a sum of the alkaline earth oxides in the glass composition. An average coefficient of thermal expansion of the glass composition is 75×10?7/° C. to 88×10?7/° C. over a temperature range from about 20° C. to about 300° C. The glass composition comprises a softening point less than or equal to 660° C. The glass composition comprises a hydrolytic resistance of class HGA1 or class HGA2 according to ISO 720:1985.

Abstract: A photochromic glass, comprising: (i) a glass matrix that, comprising in mol percent (mol %) based on oxides: 66 mol %?SiO2?75 mol %; 8 mol %?B2O3?13 mol %; mol %?Al2O3?7 mol %; 1.5 mol %?P2O5?6 mol %, mol %?Na2O?5.5 mol %; 3 mol %?K2O?9.5 mol %; 0 mol %?MgO?4 mol %; 0 mol %?Li2O?0.05 mol %; 0 mol %?BaO?0.05 mol %; 0 mol %?CaO?0.05 mole %; wherein the amount of (Li2O+BO+CaO?0.1 mole %); and (ii)) a plurality of photochromic agents, comprising in mol percent (%) with respect to the glass matrix: 0.07%?Ag?0.15%; 0.14%?Cl?0.25%; 0.025%?Br?0.04%; 0.0065%?CuO?0.015%, and wherein CuO/Ag?0.22.

Abstract: Compounds, compositions, articles, devices, and methods for the manufacture of light guide plates and back light units including such light guide plates made from glass. In some embodiments, light guide plates (LGPs) are provided that have similar or superior optical properties to light guide plates made from PMMA and that have exceptional mechanical properties such as rigidity, CTE and dimensional stability in high moisture conditions as compared to PMMA light guide plates.

Abstract: The embodiments described herein relate to low temperature moldable sheet forming glass compositions and glass articles formed from the same. In various embodiments, the glass composition comprises from about 60 mol. % to about 67 mol. % SiO2, from about 6 mol. % to about 11 mol. % B2O3, from about 4.5 mol. % to about 11 mol. % Li2O, Al2O3, Na2O, and K2O. The glass composition also includes greater than about 2 mol. % RO, where RO are divalent metal oxides, and R2O from about 14 mol. % to about 20 mol. %, where R2O are alkali metal oxides. The glass composition also has a glass transition temperature Tg of less than about 500 C., a softening point of less than about 650 C, and a coefficient of thermal expansion (CTE) of less than about 85×10?7K?1.

Abstract: In embodiments, a glass composition may include: greater than or equal to 71 mol. % and less than or equal to 83 mol. % SiO2; greater than or equal to 1 mol. % and less than or equal to 11 mol. % Al2O3; greater than or equal to 5 mol. % and less than or equal to 18 mol. % alkali oxide, the alkali oxide comprising greater than 3 mol. % Li2O and at least one of Na2O and K2O; greater than or equal to 1 mol. % and less than or equal to 8 mol. % alkaline earth oxide, the alkaline earth oxide comprising MgO and at least one of CaO, BaO, and SrO; and at least one of TiO2, ZrO2, HfO2, La2O3 and Y2O3, wherein TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than 0 mol. % and less than or equal to 6 mol. % and Al2O3+TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than or equal to 2 mol. % and less than or equal to 12 mol. %.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

Abstract: A photochromic glass that includes a base glass and a photochromic agent is described. The base glass is a modified boroaluminosilicate glass and the photochromic agent is a nanocrystalline cuprous halide phase. The photochromic glass exhibits a sharp cutoff in the UV or short wavelength visible portion of the spectrum along with an absorption band at longer wavelengths in the visible. The nanocrystalline cuprous halide phase includes Cu2+, which provides states within the bandgap of the cuprous halide that permit the glass to absorb visible light. Absorption of visible light drives a photochromic transition without compromising the sharp cutoff. The nanocrystalline cuprous halide phase may optionally include Ag.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: A multi-pane window having a low emissivity layer and a photochromic glass. The window includes at least two panes of glass. An outside pane for interaction with the outdoors and an inside pane spaced apart from the outside pane. The outside pane includes a low emissivity coating. The inside pane includes a photochromic glass. The outside pane transmits solar light wavelengths. The photochromic glass is darkened upon exposure to light transmitted by the outside pane.

Abstract: Compounds, compositions, articles, devices, and methods for the manufacture of light guide plates and back light units including such light guide plates made from glass. In some embodiments, light guide plates (LGPs) are provided that have similar or superior optical properties to light guide plates made from PMMA and that have exceptional mechanical properties such as rigidity, CTE and dimensional stability in high moisture conditions as compared to PMMA light guide plates.

Abstract: A photochromic glass that includes a base glass and a photochromic agent is described. The base glass is a modified boroaluminosilicate glass and the photochromic agent is a nanocrystalline cuprous halide phase. The photochromic glass exhibits a sharp cutoff in the UV or short wavelength visible portion of the spectrum along with an absorption band at longer wavelengths in the visible. The nanocrystalline cuprous halide phase includes Cu2+, which provides states within the bandgap of the cuprous halide that permit the glass to absorb visible light. Absorption of visible light drives a photochromic transition without compromising the sharp cutoff. The nanocrystalline cuprous halide phase may optionally include Ag.

Abstract: A photochromic glass that includes a base glass and a photochromic agent is described. The base glass is a modified boroaluminosilicate glass and the photochromic agent is a nanocrystalline cuprous halide phase. The photochromic glass exhibits a sharp cutoff in the UV or short wavelength visible portion of the spectrum along with an absorption band at longer wavelengths in the visible. The nanocrystalline cuprous halide phase includes Cu2+, which provides states within the bandgap of the cuprous halide that permit the glass to absorb visible light. Absorption of visible light drives a photochromic transition without compromising the sharp cutoff. The nanocrystalline cuprous halide phase may optionally include Ag.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: A photochromic glass that includes a base glass and a photochromic agent is described. The base glass is a modified boroaluminosilicate glass and the photochromic agent is a nanocrystalline cuprous halide phase. The photochromic glass exhibits a sharp cutoff in the UV or short wavelength visible portion of the spectrum along with an absorption band at longer wavelengths in the visible. The nanocrystalline cuprous halide phase includes Cu2+, which provides states within the bandgap of the cuprous halide that permit the glass to absorb visible light. Absorption of visible light drives a photochromic transition without compromising the sharp cutoff. The nanocrystalline cuprous halide phase may optionally include Ag.

Abstract: Embodiments are directed to glass frits containing phosphors that can be used in LED lighting devices and for methods associated therewith for making the phosphor containing glass frit and their use in glass articles, for example, LED devices.